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Abstract
An important effort has been performed after the emergence of severe acute respiratory syndrome
(SARS) epidemic in 2003 to diagnose and prevent virus spreading. Several types of vaccines have
been developed including inactivated viruses, subunit vaccines, virus-like particles (VLPs), DNA
vaccines, heterologous expression systems, and vaccines derived from SARS-CoV genome by
reverse genetics. This review describes several aspects essential to develop SARS-CoV vaccines,
such as the correlates of protection, virus serotypes, vaccination side effects, and bio-safeguards that
can be engineered into recombinant vaccine approaches based on the SARS-CoV genome. The
production of effective and safe vaccines to prevent SARS has led to the development of promising
vaccine candidates, in contrast to the design of vaccines for other coronaviruses, that in general has
been less successful. After preclinical trials in animal models, efficacy and safety evaluation of the
most promising vaccine candidates described has to be performed in humans.
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1. Introduction
Severe acute respiratory syndrome (SARS) is an infectious disease caused by a coronavirus
(SARS-CoV) (Marra et al., 2003; Rota et al., 2003). SARS was detected for the first time in
the Guandong province of China in late 2002, spread rapidly around the World and resulted in
more than 8000 cases, 10% of which resulted in death, in 33 countries, and areas of five
continents (http://www.cdc.gov/mmwr/mguidesars.en.html). World Healh organization
(WHO) declared the end of the SARS outbreak in July 5th 2003, nevertheless, several isolated
outbreaks subsequently occurred because of accidental contaminations in laboratories of
Taiwan, Singapore, and mainland China (http://www.who.int/csr/sars/en/). In late 2003 and
early 2004, newly infected persons who had contact with animals infected with SARS-CoV
strains significantly different from those predominating in the 2002–2003 outbreak were
reported in Guandong, China (Peiris et al., 2004). These events indicate that a SARS epidemic
may recur at any time in the future, although this event most likely would require the generation
of new isolates evolving from SARS-CoV-like virus circulating in animals (Jiang et al.,
2005). As a consequence of this possibility, and because SARS-CoV could be used as a
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biological weapon, it has been declared as a category C priority pathogen by the National
Institute of Allergy and Infectious Diseases Biodefense
(http://www2.niaid.nih.gov/Biodefense/bandcpriority.htm).
SARS-CoV infection results in severe acute respiratory disease, pneumonia, diarrhea, and
sometimes death (Peiris et al., 2003). SARS-CoV is a zoonotic virus that crossed the species
barrier, most likely originating from bats, and has been amplified in other species, preferentially
civets (Lau et al., 2005; Li et al., 2005; Woo et al., 2006). The SARS-CoV like viruses that
exist in animals do not cause typical SARS-like disease in the natural host and are not easily
transmitted from animals to humans. Under certain conditions, the virus may have evolved
into the early human SARS-CoV, with the ability to be transmitted from animals to humans
and from humans to humans, resulting in localized outbreaks and mild human disease (Jiang
et al., 2005). In fact, the virus most likely crossed the species barrier before the 2002 outbreak,
as sera samples collected in 2001 were positive in 1.8% of the cases (Zheng et al., 2004).
Furthermore, 40% of animal traders, whereas only a 5% of vegetable traders in Guandong
markets were seropositive for SARS-CoV without showing signs of disease (Guan et al.,
2003).
SARS-CoV vaccines are urgently needed to prevent potential SARS epidemics. As SARS-
CoV disease severity has been linked to age, with higher mortalities for ages over 45, special
attention should be paid to vaccine development to protect elderly people. Several types of
vaccines are being developed, including inactivated viruses, subunit vaccines, virus-like
particles (VLPs), DNA vaccines, heterologous expression systems, and vaccines derived from
SARS-CoV genome by reverse genetics. This paper will review previously published SARS
vaccination strategies and announce new accomplishments in SARS-CoV based vaccination
approaches while focusing on the correlates of protection, detected serotypes, vaccination side
effects, and bio-safeguards that can be engineered into recombinant vaccine approaches based
on the SARS-CoV genome.
2. Complexity of SARS-CoV serotypes
Knowledge on the diversity of serotypes is essential information for vaccine design.
Phylogenetic analysis of SARS-CoV isolates from animals and humans strongly suggest that
the virus originated from animals, most likely bats (Lau et al., 2005; Li et al., 2005; Poon et
al., 2005), was amplified in palm civets, and transmitted to human population via live animal
markets (Kan et al., 2005).
The neutralization of a set of eight pseudoviruses expressing the spike glycoprotein of eight
SARS-CoV strains selected from the three phases of the SARS epidemic (early, middle and
late), plus another human isolate collected at the end of 2003 (GD03), and two civet cat isolates
from 2003 (SZ16 and SZ3) has been studied (Chinese-Consortium, 2004; Yang et al., 2005).
Human monoclonal antibodies against the S protein of the Frankfurt isolate (FRA-1), derived
from Epstein-Barr virus transformed B lymphocytes were used. The virus tested in the
neutralization assays included pseudotypes made with the S protein from members of the four
main genetic clusters defined with the Bayesian analysis of the SARS-CoV glycoproteins (Fig.
1A) (Deming et al., 2006):
i. Group 1, originating from animals isolated in 2003. A prototype of this group is the
isolate SZ16 which primarily uses civet but not human angiotensin-converting
enzyme 2 (ACE2) as a receptor.
ii. Group 2, low pathogenic viruses originating from civets, raccoon dogs, or sporadic
human cases, such as strain GD03 reported from a sporadic SARS case in December
22, 2003. This virus represented an independent introduction of a less pathogenic
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virus, having an S glycoprotein sequence that is the most divergent of all human strains
(Chinese-Consortium, 2004). In general, group 2 isolates appear to have a receptor
binding domain (RBD) that is capable of recognizing the human ACE2 receptor, and
have been successfully cultured. GD03 S glycoprotein contains 18 amino acid
substitutions relative to group 3 Urbani S protein, many of which map within
neutralizing epitopes between amino acids 130–150 and 318–510, corresponding to
the RBD. Recombinant viruses encoding the GD03 S glycoprotein have been isolated
using reverse genetics (Baric et al., 2006). Recombinant icGD03 virus replicates about
0.5–1.0 logs less efficiently in human airway epithelial cells (6.8 × 107 PFU/ml) as
compared to wt Urbani (3.0 × 107 PFU/ml) at 42 h postinfection.
iii. Group 3, highly pathogenic viruses representing the 2002–2003 epidemic strains
associated with the early, middle, or late phase. Prototypes of these viruses are the
early isolate and middle isolates GZ02, and CUHK-W, respectively, and the late
Urbani, FRA-1, or Toronto 2 (TOR-2) strains.
iv. Group 4, bat SARS-CoV strains have not been successfully cultured but were
sequenced from samples taken from Rhinolophus spp. like the Chinese horseshoe bat.
These viruses differ from Urbani by about 12–22% in amino acid sequence and
generally have about 3–4 out of 13 contact interface residues with human ACE2
receptor. Using the S glycoprotein gene, an unrooted Bayesian analysis suggests that
bat strains are most closely related to early phase human strains.
Basically, all virus pseudotyped with S proteins from different strains were neutralized to the
same extent, except the human GD03 and the two civet cat isolates SZ16 and SZ3, indicating
that there were at least two human SARS-CoV serotypes, most likely originated from two
independent transmissions of the virus from civet cat to human (Baric et al., 2006; Yang et al.,
2005). It will be important to determine if recombinant viruses bearing zoonotic S glycoproteins
display similar neutralization kinetics as pseudotyped viruses bearing SARS spikes.
The SARS-CoV-like isolated from bats identified in Rhinolophus spp. has a nucleotide identity
with TOR-2 strain higher than 92% (Lau et al., 2005; Li et al., 2005). In addition, six novel
coronaviruses from six different bat species have been described (Woo et al., 2006). Four of
these coronaviruses belong to group 1, and two of them to group 2. Based on sequence data
these authors have proposed the classification of bat CoV in three subgroups (2a, 2b, and 2c).
Subgroup 2b comprises both SARS-CoV and a bat-SARS-CoV (Rp3 isolate). The sequences
of these SARS-CoV isolates differ in the S1 domain of the S protein, where sequence identity
fell to 64%. This sequence divergence in the S1 domain corroborated the serum neutralization
studies, which indicate that although bat sera have a high level of cross-reactive antibodies,
they failed to neutralize human or civet cat SARS-CoV when tested in Vero E6 cells (Li et al.,
2005). In contrast, other authors (Lau et al., 2005) have reported that 42% of the bat sera
samples tested neutralized human SARS-CoV isolate (HKU-39849) using FRhK-4 cells. The
discrepancy could be due to the presence of a different SARS-CoV-like virus serotype in the
bats studied by the two different groups, or to the two test systems used in the evaluation.
Consequently vaccine design should take into account this antigenic diversity. Interestingly,
recent characterization of the antigenic structure of SARS-CoV S protein with a large panel of
Mabs has shown that at least one epitope providing susceptibility to SARS-CoV that maps in
the RBD for ACE-2 is highly conserved in most virus strains and therefore, may confer
protection to most SARS-CoV strains (He et al., 2006).
3. Antigens involved in the protection against CoV induced infections
SARS-CoV has at least seven structural proteins (S, 3a, E, M, 7a, 7b, and N) (Fig. 2) (Huang
et al., 2006;Schaecher and Pekosz, 2006;Weiss and Navas-Martin, 2005). SARS-CoV S, 3a,
E, and M proteins are viral membrane proteins with domains exposed to the external face of
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the virus (Ito et al., 2005;Shen et al., 2005) that, in principle, could be involved in protection
by induction of neutralizing antibodies. It has been shown that proteins S and 3a induce in
vitro SARS-CoV neutralizing antibodies, with S protein being the main component of
protective immunity (Qiu et al., 2005;Saif, 2004). Although strong immune responses are
elicited against both S and N proteins (Buchholz et al., 2004;Subbarao et al., 2004;Wang et
al., 2005;Zhu et al., 2004), passive transfer studies illustrate that only S-specific antibodies
confer protection from SARS-CoV replication in the mouse model (Bisht et al., 2004;Subbarao
et al., 2004).
The relevance of S protein in protection against SARS-CoV has been reinforced by the
identification of neutralizing antibodies from convalescent patients. The majority of the
coronavirus neutralizing epitopes are located within the spike protein of the virus (Buchholz
et al., 2004; Hogan et al., 2004). Two domains are defined in the spike protein, the amino-
terminus (S1) and the carboxy-terminus (S2) halves. In some coronaviruses, but apparently
not in the case of SARS-CoV, the S protein is processed in these two halves (Weiss and Navas-
Martin, 2005; Wong et al., 2004). Recent evidence has determined that SARS-CoV
neutralization is sensitive to deglycosylation of the spike protein, suggesting that
conformational epitopes are important in antibody recognition (Song et al., 2004). The RBD
located in the S1 subunit of S protein contains multiple conformational neutralizing epitopes.
This suggests that recombinant proteins containing RBD, and vectors encoding the RBD
sequence, can be used to develop safe and effective SARS vaccines (Jiang et al., 2005). The
continuous viral epitopes targeted by antibodies in plasma samples from convalescent SARS
patients have been identified by biopanning with a M13 phage display dodecapeptide library
(Zhong et al., 2005). These epitopes converged to very short peptide fragments, one on each
of the spike, nucleocapsid, 3a, 9b and nsp3 proteins. Immunoassays found that most of the
patients (82%) that recovered from SARS developed antibodies to the epitope-rich region on
the spike S2 domain, indicating that this domain also is an immunodominant site on the S
protein. These S2-targeting antibodies were shown to effectively neutralize SARS-CoV.
Moreover, it is possible that S2-specific antibodies provided protective immunity to help the
patients recover from viral infection (Zhong et al., 2005). In fact, among the rabbit antibodies
elicited by different fragments covering the entire S protein expressed in E. coli, some of them
were specific for aa 1029–1192, which include the heptad-repeat sequence of the S2 domain
that interacts to form S protein trimers, and had neutralizing activities, indicating that this
region of the S protein also carries neutralizing epitopes.
SARS-CoV 3a protein consist of 274 amino acids, contains three putative transmembrane
domains, and is expressed on the virus and cell surface (Ito et al., 2005; Tan et al., 2004b). The
topology of 3a protein on the cell surface was experimentally determined; the first 34 aa, located
before the first transmembrane domain, are facing the extracellular matrix (Akerstrom et al.,
2006), and its C-terminal, after the third transmembrane domain (aa 134–274), is facing the
cytoplasm (Tan et al., 2004b). Interestingly, in two separate cohorts of SARS patients, one
from Taiwan (Liu et al., 2004) and the other from Hong Kong (Zhong et al., 2005), B cells
recognizing the N-terminal region of 3a protein were isolated from patients. Moreover,
significant proportion (40%) of the convalescent SARS patients examined in a dot blot assay
using a synthetic peptide with a sequence corresponding to amino acids 12–27 of the N terminus
of the protein were positive (Zhong et al., 2005). In addition, it was recently reported that the
N-terminal domain of 3a protein elicits strong and potentially protective humoral responses in
infected patients (Zhong et al., 2006). Accordingly, rabbit polyclonal antibodies raised against
a synthetic peptide corresponding to aa 15–28 of 3a protein inhibit SARS-CoV propagation in
Vero E6 cells, in contrast to antibodies specific for the C-terminal domain of the protein
(Akerstrom et al., 2006).
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SARS-CoV E, M, and 7a proteins have shown low immunogenicity (Tan et al., 2004a). Sera
from three convalescent phase SARS patients do not recognize these proteins expressed in
mammalian cells. Accordingly, SARS-CoV E protein peptides were not recognized by
convalescent patient antisera using a protein microarray (Qiu et al., 2005). In a study using
rabbit antibodies to 13 recombinant fragments associated with SARS-CoV S, E, M, N, 3a, 3b,
6, 7a, and 9b proteins, strong neutralizing antibodies were only elicited by the S1 fragment (aa
241–591) of S protein (Qiu et al., 2005). The incorrect folding of the proteins expressed in E.
coli could be responsible for the lack of detection of antibodies to other viral proteins, such as
the 3a protein that is known to induce neutralizing antibodies (see above).
The M protein of transmissible gastroenteritis coronavirus (TGEV) is required for virus
assembly and budding, and M protein specific antibodies significantly, but weakly, neutralize
TGEV and mediate complement-dependent lysis of TGEV infected cells (Delmas et al.,
1986; Risco et al., 1995; Woods et al., 1987). Consistent with the TGEV data described above,
it has been shown that SARS-CoV M protein also induced virus neutralizing antibodies in the
absence of complement (Buchholz et al., 2004). In addition, a mixture of S and M proteins
showed a synergistic effect in the in vitro synthesis of TGEV neutralizing antibodies by
immune leukocytes (Anton et al., 1995). In the case of SARS-CoV, immunization of hamsters
with a parainfluenza virus vector has shown a differential role of S, M, E, or N proteins in
protection (Buchholz et al., 2004). Parainfluenza virus expressing S protein alone provided
complete protection against SARS-CoV challenge in the lower respiratory tract and partial
protection in the upper respiratory tract. This protection was slightly augmented by co-
expression with M and E proteins (Buchholz et al., 2004). Nevertheless, expression of M, E,
or N proteins in the absence of S protein did not confer detectable protection. These results
identify S as a main SARS-CoV neutralization and protective antigen among the structural
proteins, and confers a limited role to SARS-CoV M protein in protection.
SARS-CoV N protein specific antibodies do not neutralize the virus in vitro as it could be
expected for an internal virus protein (Pang et al., 2004). However, SARS-CoV N protein
induces T-cell responses (Gao et al., 2003). Accordingly, DNA immunization using SARS-
CoV N gene induces potent Th1 polarized immune responses in mice, as well as specific
antibodies in these animals. In fact, the highest levels of humoral response and T cell
proliferation activity were induced by the N gene construct (Jin et al., 2005). Analysis of the
immune response to another coronavirus (TGEV), using an in vitro antibody synthesis system,
has shown that the optimum combination of viral proteins to stimulate the production of TGEV
neutralizing antibodies in vitro was a mixture of S and N proteins, or a combination of S protein
oligomers (rosettes) and the N or N protein-derived peptides (Anton et al., 1996; Anton et al.,
1995). These data, in principle, suggest that N protein could be used in a vaccine to promote
the synthesis of S-specific neutralizing antibodies.
9b protein (98 aa) elicits antibodies in SARS-CoV patients, indicating that it is expressed in
natural disease and that it is immunogenic (Qiu et al., 2005; Zhong et al., 2005). In fact 100%
of convalescent phase patients sera were positive for 9b protein. Based on this data, it has been
speculated that 9b protein could be structural (Qiu et al., 2005). Nevertheless, the presence of
9b protein in SARS-CoV virions needs to be further proved.
In summary, with the available data, SARS-CoV proteins S and 3a elicit strong neutralizing
antibody responses, whereas protein M only induces a reduced neutralizing humoral immune
response. These antigens probably are relevant in the protection against SARS-CoV. In
addition, other structural proteins (such as E, M, 7a, 7b, and N), and possibly protein 9b, could
also play a role in protection.
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4. Role of humoral and cellular compartments in protection against SARS
To study the role of the humoral immune response to SARS-CoV, spike specific monoclonal
antibodies that neutralize the virus have been developed (Berry et al., 2004; Subbarao et al.,
2004; Traggiai et al., 2004; Zhang et al., 2004). Passive transfer of these monoclonal antibodies
or immune serum into naïve mice protected them from infection with SARS-CoV (Subbarao
et al., 2004). Using Epstein-Barr virus transformed human B cells, the memory repertoire of a
patient who recovered from SARS-CoV infection has been rescued (Traggiai et al., 2004).
Some of the monoclonal antibodies exhibited neutralization activity in vitro, and some of them
also conferred protection in a mouse model of SARS-CoV infection. In addition, human IgG
monoclonal antibodies neutralizing SARS-CoV developed using phage display libraries
protected ferret from lung disease and virus shedding in pharyngeal secretions (ter Meulen et
al., 2004). In both mouse and ferret models, administration of human monoclonal antibodies
with in vitro neutralization activity reduced SARS-CoV titers in the lungs 3 to 6-log10-unit,
protecting from lung pathology in ferrets (ter Meulen et al., 2004). Overall, these data indicate
that humoral immune responses alone can protect against SARS.
Immune responses to SARS-CoV, elicited by a DNA vaccine encoding a codon optimized
SARS spike protein (Yang et al., 2004), or the S1 fragment, induced neutralizing antibodies
(Zeng et al., 2004), as well as T-cell responses. Nevertheless, protection from SARS-CoV
challenge was mediated by a humoral immune response but not by a T-cell-dependent
mechanism (Yang et al., 2004).
Surprisingly, immunodeficient mice can clear a SARS-CoV infection, showing the role of
innate immune responses in the defenses against SARS-CoV. C57BL/6 mice that lack NK-T
cells (CD1−/−), or NK cells, or those that lack T and B cells (Ragl−/−) cleared the virus by day
9 after infection (Glass et al., 2004) and displayed high induction of proinflammatory cytokines.
These data suggest that the NK cells and the adaptative immune response were not essential
for virus clearance in mice. Possibly, interferon pathways were relevant in viral clearance. The
importance of interferon response was reinforced by infecting Stat1-deficient mice with SARS-
CoV (Hogan et al., 2004). Stat1 is important to the regulation of interferons, and Stat1-deficient
mice produced one hundred-fold increase in viral titer over control mice. Additionally, the
mutant mice developed interstitial pneumonia, not seen in control mice (Hogan et al., 2004)
but not alveolar damage, as seen in lungs of human patients. It is unclear at this time if the
observed pathological differences between human and Stat 1-deficient mouse lungs were due
to time of sampling or to differences in host responses (Hogan et al., 2004).
5. Development of non-replicating SARS-CoV vaccines
5.1. Inactivated virus vaccines
Neutralizing antibodies were detected 2–3 weeks after the onset of disease in
immunocompetent SARS patients, and 90% of patients recovered without hospitalization
(Ksiazek et al., 2003). These data indicate that most patients successfully respond to SARS-
CoV infection. Although many types of vaccines for SARS-CoV have been attempted such as
expression of recombinant proteins, or the use of virus vectors, these vaccines require
considerable research set-up time (Bradbury, 2003). Therefore, the classical approach using
inactivated, cell-culture based SARS-CoV is likely to be the easiest way for SARS vaccine
development, based on the experience with available vaccines including inactivated or live
polio and rabies vaccines (Montagnon, 1989; Zhou et al., 2005). This is the case of companies
that favored the development of an inactivated candidate whole virus vaccine, based on the
well-established technologies for the development of such vaccines (Spruth et al., 2006).
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The fast spreading of SARS initially prompted a Chinese company (Sinovac Biotech of Beijin)
to develop a vaccine in collaboration with the Chinese Academy of Medical Sciences that
started tests of the vaccine, an inactivated form of SARS-CoV as early as 2004, using 30
volunteers (Marshall and Enserink, 2004). No side effects were reported for the first patients
that were injected with the inactivated virus.
SARS-CoV inactivation to produce the killed vaccines has been performed using different
methods. For instance, SARS-CoV purified by ultracentrifugation has been inactivated with
β-propiolactone and administered with or without Alhydrogel as adjuvant (See et al., 2006).
The virus subcutaneously administered to mice was more efficient than recombinant
adenoviruses expressing either the S or N proteins, provided by the intranasal or intramuscular
routes. An alternative method was the inactivation of SARS-CoV by β-propiolactone before
initiating the purification step. Immunization with this virus was compared with vaccination
using DNA or adenovirus vectors. The humoral immune response was most effective using
inactivated virus with adjuvants such as MF59 (Chiron Vaccines) or Alum (Pierce, Rockkford,
IL), and was associated with stimulation of the CD4 but not the CD8 response, supporting the
use of inactivated SARS-CoV as vaccine (Kong et al., 2005).
SARS-CoV has also been purified up to 98% homogeneity by ultrafiltration, gel filtration, and
exchange chromatography, and inactivated with β-propiolactone. Cynomolgus macaques were
immunized with different amounts of the purified virus in the absence or in the presence of
adjuvant. Monkeys were challenged by the nasal route 30 days post-immunization. High levels
of neutralizing antibodies that prevented the replication of SARS-CoV and interstitial
pneumonia were induced (Qin et al., 2006).
Interestingly, no side effects were observed even in the presence of low titer neutralizing
antibodies, indicating that the purified SARS-CoV vaccine is safe in monkeys.
In other approaches, SARS-CoV partially purified in sucrose cushions was completely
inactivated with formaldehyde. This virus efficiently competed the binding of infectious virus
to cells, indicating that the inactivated virus kept a functional RBS (Qu et al., 2005).
Polyethyleneglycol precipitated virus alone or in the presence of cholera toxin B (CTB, Sigma)
or CpG, administered to mice by the intranasal route elicited serum SARS-CoV-specific
neutralizing antibodies, and IgA specific antibodies in the trachea and lungs (Qu et al., 2005).
In another approach, formaldehyde inactivated whole virus, prepared in Vero cells, was used
in intramuscular immunization of 2–5 year-old rhesus monkeys (Zhou et al., 2005). After 3
weeks, monkeys were challenged with SARS-CoV. Doses of 0.5 or 5 μg/monkey protected
most of the monkeys against challenge with 108 pfu of SARS-CoV, and higher doses (50 μg)
conferred complete protection. In contrast, the control animals developed a typical SARS-CoV
infection after challenge. The immunization preferentially induced Th1 responses, but also
enhanced other cellular immune responses, including the production of IFN-γ that can increase
the activity of natural killer cells and inhibit virus replication. No systemic side effects were
observed in vaccinated animals post-immunization, even at the high dose (5000 μg/monkey)
and after two injections.
One vaccine manufactured to large scale using fermenter cultures of Vero cells in serum free
medium has been based in a double-inactivated, whole virus vaccine (Spruth et al., 2006). Virus
infection at a moi of 0.001 resulted in generation of high viral titers (around 108 TCID50/ml).
Culture supernatants were harvested and inactivated by formalin treatment followed by UV
inactivation. This two step inactivation procedure was utilized in order to ensure a high safety
margin with respect to residual infectivity. Mice immunized twice with l μg of SARS-CoV
vaccine using adjuvant (0.2% aluminium hydroxide) developed high antibody titers against
SARS-CoV spike protein, as determined by an ELISA test. The use of the adjuvant Al(OH)3
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had only a minor effect on the immunogenicity of the vaccine. In addition, cell mediated
immunity, as measured by the production of INF-γ and IL-4 stimulation, was elicited. The
vaccine confers 100% protection that was correlated to antibody titer against the SARS-CoV
S protein and to neutralizing antibody titer. Induction of neutralizing antibodies with titers
≥114 and an S-specific ELISA titer ≥25,600 resulted in 100% protection against intranasal
challenge with 105 TCID50 of infectious virus.
5.2. Subunit vaccines
A polypeptide containing amino acids 14–762 of the SARS-CoV spike protein has been
expressed using the baculovirus system (Bisht et al., 2005). The affinity purified protein was
administered to mice with either saponin or Ribi as adjuvants. Both regimens induced binding
and neutralizing monoclonal antibodies, although the best results were obtained with saponin
and polypeptide, which provided the highest antibody response. After challenge, protective
immunity was shown by the reduction of SARS-CoV titers in the upper and lower respiratory
tract. This subunit vaccine induced higher neutralizing antibody and more complete protection
against an intranasal challenge than that achieved by inoculation of mice with live SARS-CoV
(Subbarao et al., 2004), vaccinia virus Ankara (MVA) expressing the full length S protein
(Bisht et al., 2004), or DNA expressing the full-length S or S protein lacking the transmembrane
and cytoplasmic domains (Yang et al., 2004).
N protein by itself does not provide protection against SARS-CoV infections. Still, a large
number of reports using N protein as an antigen have been published. The immune response
of mice vaccinated with a purified N protein fused to glutathione S-transferase (GST) was
analyzed and compared with the response of two DNA-based vaccination approaches (Gupta
et al., 2006). The immunization with N-GST elicited a strong T-cell IL-4, and antibody
responses but minimal IFN-γ response. This response differed markedly with the immune
response shown by mice immunized with both DNA encoding unmodified cytoplasmic N
protein, and DNA encoding N as a LAMP-1 chimera targeted to the lysosomal MHC II
compartment. DNA immunizations elicited a strong T-cell IFN-γ and CTL responses.
Nevertheless, the T-cell responses to the three immunogens were elicited by the same N
peptides as shown by the ELISPOT analysis of antigen-activated T cells. In vivo protection
experiments were not performed with these vaccines.
The N protein of SARS-CoV was expressed in E. coli and purified (Liu et al., 2006). Balb/c
mice were vaccinated with N protein emulsified in Montanide ISA-51 containing the
oligodeoxynucleotide CpG, or in PBS. In the first case, anti-N antibodies were found to be
mainly IgG2a, suggesting a prevalence of Th1 immune response. In contrast, anti-N protein
antibodies of mice immunized with N protein in PBS were found to be mainly IgG1. Reactivity
of antisera raised against N protein formulated in ISA-51/CpG in mice and monkeys and that
of sera from patients were tested with a panel of overlapping peptides. The region around
residues 156–175 of N protein is immunogenic in the three models. In addition, peptides
corresponding to residues 1–30, 86–100, 306–320 and 351–365 contained murine
immunodominant T-cell epitopes. Using and IFN-γ secretion cell assay, peptides containing
residues 81–95 were capable of stimulating CD4+ and CD8+ cell proliferation in vitro. Peptides
corresponding to residues 336–350 were capable of stimulating INF-γ production in T-cell
cultures derived from peripheral blood mononuclear cells (PBMCs) of macaques immunized
with the N protein emulsified in ISA-51/CpG. No protection experiments were performed with
this immunogen.
5.3. Virus like particles (VLPs)
The requirements for SARS-CoV VLP formation differs using different expression systems
and cell types. Production of viral proteins in insect cells using baculovirus has shown
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intracellular SARS-CoV VLPs assembly by expressing M and E proteins (Ho et al., 2004).
Secretion of these VLPs to the extracellular media required the co-expression of S protein
(Mortola and Roy, 2004). In these experiments secretion of VLPs was relatively efficient (200
μg per 1 × 109 infected cells). These results are at variance with those obtained by expressing
SARS-CoV proteins in human 293 renal epithelial cells under the control of cytomegalovirus
promoter, using DNA plasmids (Huang et al., 2004). In this system, any combination of genes
that expressed M and N proteins, with or without S or E proteins, generated intracellular VLPs,
and the pseudoparticles did not form in the absence of the M and N proteins. No single viral
gene was able to support the formation of viral capsids within these cells. The additional
expression of the S protein allowed the formation of budding particles with morphology typical
of SARS and related coronaviruses. Different types of VLPs could be formed depending of
the protein composition of these SARS-CoV VLPs. Protection by the administration of VLPs
has not been reported.
6. Vaccines produced in plants
The development of plant-based vaccines against different coronaviruses [TGEV, infectious
bronchitis virus (IBV), and porcine epidemic diarrhea virus (PEDV)] using the oral delivery
of recombinant S protein that elicit protective immunity has been reported (Bae et al., 2003;
Lamphear et al., 2004; Tuboly et al., 2000; Zhou et al., 2003). One of these studies include a
S protein plant-based vaccine candidate against TGEV that has advanced into early phase
farming trials (Tuboly et al., 2000). More recently, to develop a safe, effective, and an
inexpensive vaccine candidate, the S1 domain of SARS-CoV S protein has been expressed in
tomato and low-nicotine tobacco plants (Pogrebnyak et al., 2005). High expression levels of
recombinant S1 protein (>0.1% total soluble protein) were observed in several transgenic lines
by Western blot analysis using S protein specific antibodies. Plant-derived antigen induced
systemic and mucosal immune responses in mice, which showed significantly increased levels
of SARS-CoV specific IgA after oral ingestion of tomato fruits expressing S1 protein
(Pogrebnyak et al., 2005). Sera of mice parenterally primed with tobacco-derived S1 protein
revealed the presence of SARS-CoV-specific IgG.
7. DNA vaccines
Several approaches based on DNA vaccination have been described in order to elicit protection
against SARS. Two of them used prime-boost strategies and showed that the combination of
the DNA vaccine and the whole chemically inactivated vaccine can be used to enhance the
magnitude of the immune response, and also to change the balance of humoral to cellular
immune response (Zakhartchouk et al., 2005a). A combination of the DNA and inactivated
virus induces Th1 immune responses while the whole killed virus vaccine induces Th2 immune
responses.
Mice immunized intramuscularly with a DNA vaccine expressing S protein and
intraperitoneally boosted with E. coli expressing S peptides showed high neutralization titers
(>1:1280). This vaccine might have a practical value to immunize in farms growing civet cats
due to its low cost (Woo et al., 2005).
Other DNA vaccines express N protein alone or linked to calreticulin. The first ones
preferentially induce IgG responses of the IgG2a isotype, IFN-γ and IL-2, and CD8+ CTL
responses to N protein, but produce strong delayed-type hypersensitivity (DTH) that could
have undesired side effects (Zhao et al., 2005). The expression of N protein linked to
calreticulin increases major histocompatibility complex (MHC) class I presentation to CD8+
T cells, in the absence of reported adverse effects in mice (Kim et al., 2004). These vaccines
led to the generation of strong N-specific humoral and T-cell-mediated immune responses in
mice, but no protection experiments were shown. N protein has also been expressed linked to
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hLAMP (N-hLAMP), that target antigen to the MHC class II, leading to a stronger and higher
memory cellular immune response associated to high IFN-γ production than immunization
with N protein alone (Gupta et al., 2006).
Studies on DNA immunization to protect against SARS, using three forms of the spike protein:
full-length S, and S proteins with the cytoplasmic or the transmembrane domains deleted have
been reported (Yang et al., 2004). These vaccines induced neutralizing antibodies and T-cell
responses, resulting in protective immunity in mice. Viral replication was reduced more than
six orders of magnitude in the lungs of mice vaccinated with these S plasmid DNA expression
vectors. Protection was mediated by a humoral but not a T-cell dependent immune mechanism,
as shown by adoptive T-cell transfer in which donor T-cells were unable to reduce pulmonary
viral replication in recipient animals. By contrast, passive transfer of purified IgG from
immunized mice, but not control IgG provided immune protection against SARS-CoV (Yang
et al., 2004). The vector expressing the S protein with the cytoplasmic domain partially deleted
induced the most potent neutralizing antibody response.
8. Development of SARS-CoV vaccines based on viral expression vectors
8.1. Poxvirus expression vector based vaccines
Using the highly attenuated modified MVA, SARS-CoV S protein has been expressed by
several groups (Bisht et al., 2004; Chen et al., 2005). The first one has shown that intranasal
or intramuscular immunization of Balb/c mice elicited protective immunity as shown by the
reduction of SARS-CoV titers in the upper and lower respiratory tract after challenge.
Furthermore, passive transfer of serum from mice immunized with the recombinant MVA
expressing S protein to naïve mice also reduced the replication of SARS-CoV in the respiratory
tract after challenge, demonstrating a role for S protein specific antibodies in protection. The
second group (Chen et al., 2005) showed the induction of neutralizing antibodies in mice,
ferrets, and monkeys, although protection experiments were not performed. In an antibody
absorption assay, the majority of the antibodies raised by the MVA recombinant expressing
the full-length S protein were absorbed by an S protein fragment including aa 400–600, that
includes the RBD, indicating that the major SARS-CoV neutralization mechanism likely
occurs through blocking the interaction between the virus and the cellular receptor ACE2.
In contrast, other authors immunized ferrets using MVA expressing the SARS-CoV S protein,
inducing a vigorous immune response that did not prevent virus infection and spreading (Czub
et al., 2005; Weingartl et al., 2004). Liver inflammation was found in all MVA-spike vaccinated
ferrets. These authors suggested that their results indicate the induction of antibody dependent
enhancement (ADE) of disease similar to that caused by feline infectious peritonitis virus
(FIPV).
8.2. Adenovirus vector based vaccines
SARS vaccines based on the use of adenovirus vectors have shown that expression of S protein
alone or in combination with N protein led to the protection of mice against the challenge with
SARS-CoV. The efficacy of immunization with adenovirus vectors was compared with that
of chemically inactivated partially purified virus. Whole-killed virus vaccine was more
effective in conferring protective immunity against live SARS-CoV (See et al., 2006). Other
adenovirus vaccines tested in mice have expressed either the S or the N protein (Zakhartchouk
et al., 2005b) and shown that the S2 domain and the N protein contain strong T-cell epitopes,
but reported no challenge experiments. In the monkey model, adenovirus-based vaccines
induce strong SARS-CoV-specific immune responses, indicating that these vectors are
promising vaccine candidates but, again, no information on protection have been provided
(Gao et al., 2003). The adenovirus Ad5 vector with a deletion in the E1 and E3 regions, have
Enjuanes et al. Page 10
Virus Res. Author manuscript; available in PMC 2009 January 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
also been used to express the S1 domain of the SARS-CoV S protein (490 aa) (Liu et al.,
2005). Wistar rats immunized three times throughout consecutive weeks produce antiserum
capable of protecting from SARS-CoV infection in cell culture. Histopathological examination
found no evident side effects in the immunized animals. Nevertheless, in vivo protection
experiments were not performed. Therefore, additional experiments are required with the
adenovirus based SARS vaccines.
8.3. Venezuelan equine encephalitis (VEE) virus vector based vaccines
Severe disease and high death rates were noted in senescent human populations infected with
SARS-CoV, while children under 12 years of age did not develop the severe disease that was
seen in adults (Baric et al., 2006; Deming et al., 2006; Ng et al., 2004). These data suggest that
the quality of the immune response may play a role in the outcome of virus infection. The
ability of vaccines to induce robust immune responses in senescent populations has been
evaluated to determine if protection can be elicited in elderly populations with senescent
immune systems. To evaluate vaccine efficacy against homologous and heterologous strains,
the Urbani S glycoprotein and nucleocapsid genes were inserted in VEE virus replicon particles
(VRP-S or VRP-N) (Baric et al., 2006; Deming et al., 2006). In addition, expression of the
influenza A HA glycoprotein (VRP-HA) was used as a control. Using reverse genetics,
synthetically resurrected recombinant viruses bearing the GD03 S glycoprotein that replicated
to high titers in Vero and human airway epithelial cells have been obtained (Baric et al.,
2006; Deming et al., 2006). Importantly, human convalescent sera had plaque reduction
neutralization titre of 50% (PRNT50) values of about 1:1600 against late phase isolates like
Urbani, yet were reduced about 10–15 fold against the heterologous icGD03 virus (PRNT50
1:150) (Fig. 3A). Young and senescent Balb/c mice with ages exceeding 1 year at the time of
challenge, were vaccinated with VRP-HA, VRP-S, VRP-N, or a combination of VRP-S and
VRP-N, and challenged with recombinant SARS-CoV expressing the Urbani S protein or the
antigenically different GD03 S protein (Fig. 3B). In vaccinated animals, VRP-S vaccines
provided complete short- and long-term protection against homologous challenge, protecting
both young and senescent mice from the Urbani strain replication. After challenge, VRP-S and
VRP-S + VRP-N vaccinated mice displayed little if any pathologic lesions in the lung, whereas
VRP-HA vaccinated aged mice demonstrate pathological lesions in the lung similar to that
reported in the literature (Roberts et al., 2005a). VRP-S vaccines also provided short-term
protection in young mice challenged with the heterologous GD03 S strain, despite the
significantly reduced ability of anti-Urbani S antibody to neutralize virus expressing GD03 S.
In contrast, vaccination of senescent mice with VRP-S provided limited protection (~38%) and
the combination of VRP-S + VRP-N vaccines provided little long-term protection against
infection by the antigenically different SARS-CoV GD03, although virus titers were reduced
about 10-fold compared with VRP-HA controls. The SARS-CoV GD03 challenge also
produced pathological lesions in both the VRP-HA and SARS-vaccinated animals that were
virtually indistinguishable from those produced by infection with the SARS-CoV-Urbani
strain. Therefore, it is likely that declining immunity of senescent animals in combination with
the reduced ability of antibody to neutralize heterologous challenge viruses resulted in vaccine
failure in aged animals. It seems that vaccine approaches that induce less robust neutralization
responses like DNA and killed vaccines, might completely fail in protecting senescent
populations against SARS-CoV GD03 challenge.
SARS-CoV disease severity was linked to age and other co-morbidities, with mortality rates
increasing with age and exceeding 50% in individuals over 65. It is also known that elderly
respond poorly to new antigens as compared to younger populations, but overall this
phenomena is poorly studied. Consequently, vaccine efficacy in the elderly is a key property
of efficacious SARS-CoV vaccines. Immunosenescence is common in animal models and in
clinical studies that occur during aging, and vaccine efficacy is often attenuated in the elderly
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(Frasca et al., 2005; Song et al., 1997; Zheng et al., 1997). Immune complications include a
generalized decrease in the function of B and T cell and innate immune function, diminished
macrophage and granulocyte function, diminished cellular traffic, cell growth and
differentiation and decreased natural killer cell numbers and activity. New and different vaccine
regimens should be developed and tested with the ultimate goal of eliciting complete protection
against antigenically heterologous forms of SARS-CoV, especially in the most vulnerable
elderly populations, and that there is a need for further testing developing vaccines that induce
an anti-N response in more animal models, similarly to what has been described in other viral
systems (Frech et al., 2005; McElhaney, 2005).
8.4. Parainfluenza based vectors
A vector based in an existing live attenuated parainfluenza virus, that is being developed for
intranasal pediatric immunization against human parainfluenza virus type 3 (HPIV3) was used
to express SARS-CoV S protein (Bukreyev et al., 2004). Vector administration to monkeys
resulted in the production of systemic immune response by mucosal immunization. After
challenge with SARS-CoV, all monkeys in the control group shed SARS-CoV. In contrast, no
viral shedding occurred in the group immunized with the parainfluenza vector expressing the
S protein. Recombinant viruses expressing SARS-CoV structural S, M, and N proteins,
individually or in combination, have been evaluated for immunogenicity and protection in
hamsters that support the replication of both SARS-CoV and parainfluenza vector (Buchholz
et al., 2004). A single intranasal administration of the vector expressing the S glycoprotein
induced a high titer of SARS-CoV neutralizing antibodies, only two fold lower than that
induced by SARS-CoV infection. This response provided complete protection against SARS-
CoV challenge in the lower respiratory tract, and partial protection in the upper respiratory
tract. In contrast, expression of M, N, or E proteins did not induce detectable serum SARS-
CoV neutralizing antibodies.
8.5. Rhabdovirus based vector
A recombinant rabies virus vector has been used to express the S protein of SARS-CoV (Faber
et al., 2005). Immunogenicity studies in mice showed the induction of SARS-CoV neutralizing
antibodies after a single dose, but no protection studies have been shown. Similarly, an
attenuated vesicular stomatitis virus (VSV) vector was used to express the S protein of SARS-
CoV (Kapadia et al., 2005). Mice vaccinated with VSV-S developed SARS-CoV neutralizing
antibodies that controlled challenge with SARS-CoV performed at 1 or 4 months after a single
vaccination.
In summary, immunization to prevent SARS using different live vector systems has shown
that protection is mainly mediated by humoral immune responses to the S protein. A warning
signal was that, at least with some vectors such as VEE virus, the expression of N protein may
lead to side effects.
9. SARS-CoV vaccine candidates engineered by reverse genetics
9.1. Vaccines based on the deletion of single or several accessory combinations of genes
The effect of the deletion of group-specific genes in different coronaviruses has been studied.
Reports using mouse hepatitis virus (MHV) as a model have shown that deletion mutants
removing ORFs 4, 5a, 7a, and HE are attenuating in the natural host (de Haan et al., 2002a).
Similarly, studies deleting ORF 7 of TGEV (Ortego et al., 2003) and ORFs 3abc and 7ab of
FIPV (Haijema et al., 2004) led to virus attenuation. However, SARS-CoV deletion mutants
lacking ORFs 3a, 3b, 6, 7a, or 7b did not significantly influence in vitro and in vivo replication
efficiency in the mouse model (Yount et al., 2005). All recombinant viruses replicated to wild-
type levels in the murine model, suggesting that either the group-specific ORFs play little role
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in in vivo replication efficiency or that the mouse model is not of sufficient quality for
discerning the role of the group-specific ORFs in disease. In fact it has been surprising that
ORFs like 3a, 7a, and 7b, that encode structural virus proteins, (Huang et al., 2006; Schaecher
and Pekosz, 2006; Yount et al., 2005) have little influence on in vivo virus replication in the
mouse model. Only deletion of ORF 3a has shown a minor decrease (about one log unit) in
virus growth (Yount et al., 2005). Furthermore, deletion of more than one gene, such as deletion
of ORFs 3a and 3b, and ORF6, showed a 1–1.5 log reduction in Vero cells but little effect on
growth in the murine model at day 2 postinfection. Moreover, little difference in growth or
pathogenesis were noted in the mice model between wt and deletion mutants lacking ORF3a
and ORF7. Therefore, the effect of SARS-CoV gene deletions needs to be tested in more
relevant animal models. Interestingly, the simultaneous deletion of larger combinations of
group-specific genes such as 6, 7a, 7b, 8a, 8b, and 9b has lead to the production of an infectious
SARS-CoV deletion-mutant that propagates in cell culture with a titer similar to that of the
parental wild type virus. The potential of this deletion-mutant as a promising vaccine candidate
is being studied (M.L. DeDiego, and L. Enjuanes, unpublished results).
9.2. Vaccines based on the deletion of structural proteins
A recombinant SARS-CoV (rSARS-CoV) that lacks the E gene generated from a bacterial
artificial chromososme (BAC) was attenuated in vitro and in an animal model (DeDiego et al.,
2007). The E gene was previously shown to be a non-essential gene for the group 2 MHV
coronavirus (Kuo and Masters, 2003), although elimination of this gene from MHV genome
reduced virus growth in cell culture more than one thousand-fold. In contrast, for group 1
TGEV coronavirus, expression of the E gene product was essential for virus release and spread.
Propagation of E gene deleted TGEV (TGEV-ΔE) was restored by providing E protein in
trans (Curtis et al., 2002; Ortego et al., 2002).
The role of E protein in SARS-CoV propagation was studied by constructing SARS-CoV with
a deleted E gene (DeDiego et al., 2007). Interestingly, viable viruses were recovered in Vero
E6 cells with a relatively high titer (around 106 pfu/ml) and also from Huh-7 and CaCo-2 cells
with reduced titers (Fig. 4), indicating that SARS-CoV E protein is not essential for virus
replication in cell culture. Electron microscopy observation of Vero E6 cells infected with the
SARS-CoV wt or the ΔE deletion mutant showed much higher assembly efficiency for the
wt virus (Fig. 5). In this respect, SARS-CoV-ΔE behaves as MHV, the other group 2
coronavirus studied, although SARS-CoV-ΔE grows to a considerably higher titer. The
differential behavior of ΔE mutant viruses from different coronavirus groups may indicate
basic differences in virion assembly or life cycles among the different groups.
The hamster model has been used to study SARS-CoV-ΔE virus pathogenicity, because it
demonstrates elements present in human cases of SARS-CoV infections including interstitial
pneumonitis and consolidation (DeDiego et al., 2007). An ideal animal model that completely
reproduces human clinical disease and pathological findings has not been identified.
Nevertheless, the hamster model reproducibly supports SARS-CoV replication in the
respiratory tract to a higher titer and for a longer duration than in mice or non-human primates.
Virus replication in this model is accompanied by histological evidence of pneumonitis, and
the animals develop viremia and extrapulmonary spread of virus (Roberts et al., 2005b).
Although overt clinical disease is absent, the hamster model is a useful model for the evaluation
of SARS-CoV infection. Titers of recombinant SARS-CoV (rSARS-CoV) achieved in the
respiratory tract of hamsters (Fig. 6) were similar to those previously reported (Roberts et al.,
2005b) and were 100–1000-fold higher than titers of the rSARS-CoV-ΔE virus, suggesting
that this mutant virus is attenuated. Histopathology examination of lungs from infected
hamsters was performed at two and five days post-infection, because it has been shown that
pulmonary disease was most notable at these time points. Detection of viral antigen was
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reduced in lungs from rSARS-CoV-ΔE infected hamsters and pulmonary inflammation was
less prominent in these animals than in rSARS-CoV-infected animals, indicating that rSARS-
CoV-ΔE is attenuated in vivo (DeDiego et al., 2007). In fact, reduction of SARS-CoV titers in
patients has been associated with a considerable reduction in pathogenicity and survival rates
(Chu et al., 2004; Hung et al., 2004). In contrast, challenge of hamsters with recombinant
viruses lacking single group specific ORFs3a and ORF7 did not result in significant reductions
in virus titier or pathology (Baric et al., unpublished). Therefore, SARS-CoV-ΔE attenuated
virus is a promising vaccine candidate that is being evaluated in different animal models (mice,
ferrets and macaques).
9.3. Future trends on SARS-CoV reverse genetic vaccines
Live attenuated virus vaccines face a series of potential concerns including reversion to wt and
recombination repair with circulating heterogeneous human coronaviruses or zoonotic SARS
strains. Consequently, live virus vaccine formulations should include rational approaches for
minimizing the potential for reversion to wt phenotype and simultaneously resist recombination
repair. It is clear that modifications of SARS-CoV genome could lead to viruses with an
attenuated phenotype that could be considered safe and effective vaccine candidates. The
replicase as a target for attenuating coronaviruses is undiscovered territory, likely ripe with
alleles that might influence replication efficiency and virulence. The SARS-CoV replicase
represents a major target of future research endeavors.
Coronaviruses have a characteristic, strictly conserved genome organization with structural
genes occurring in the order 5′-polymerase (pol)-S-E-M-N-3′. MHV virus mutants with the
genes encoding the structural proteins located in different order were constructed (de Haan et
al., 2002b). These recombinant viruses were tested for the ability to replicate in the natural
host, the mouse. The results indicate that the canonical coronavirus genome organization is not
essential for in vivo replication. Some of the mutants showed an attenuated phenotype, similarly
to what has been observed for the VSV (Ball et al., 1999). Therefore, deliberate rearrangement
of the viral genes may be useful in the generation of attenuated coronaviruses, which due to
their reduced risk of generating viable viruses by recombination with circulating field viruses
would make safer vaccines.
Vaccines based on modifications of the replicase gene could in principle be generated by
mutagenesis, as modifications introduced in the MHV nsp-1coding regions have identified
residues important for protein processing and viral RNA replication that may affect virus
virulence and could be introduced in vaccine candidates (Brockway and Denison, 2005). SARS
nsp1 blocks host macromolecular synthesis and abrogates IFN signaling (Kamitani et al.,
2006), providing further evidence that nsp1 coding regions represent potential virulence
determinants. Alternatively, Tyr6398His substitution in open reading frame (ORF) 1b-nsp14
has been demonstrated that attenuate MHV replication in mice (Sperry et al., 2005). Similarly,
deletion of the nsp2 gene in MHV and SARS-CoV has been shown to yield viable attenuated
mutant viruses that replicate about one log less efficiently than wt virus in cell culture and in
animals, and may also provide a foundation for the design of live vaccines (Graham et al.,
2005). As the nsp14 Tyr residue and nsp 2 are completely conserved, it may be possible to
engineer common Coronaviridae attenuating alleles via recombinant DNA techniques.
Alternatively, changes in gene order within the replicase or even relocation to the 3′-end of the
genome, if tolerated, may led to attenuated virus phenotypes.
Other options to include safeguards into the genetically engineered vaccines, particularly those
that can prevent the recovery of the original virulent phenotype by recombination between the
vaccine strain and viruses circulating in the field (such as HCoV-229E, -OC43, or -NL63) have
been developed. One of them is the construction of replication-competent, propagation-
defective viruses (pseudovirions) that are defective in one gene conferring an attenuated
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phenotype or even the ability for virus propagation (Enjuanes et al., 2005). These viruses could
be grown in packaging cell lines providing in trans the missing protein. In the case of SARS-
CoV, vaccine candidates without the E gene have been constructed. In order to prevent the
rescue of the virulent phenotype by recombination with a circulating human coronavirus, the
deletion of an essential gene, located in a position distant from gene E, and the relocation of
the deleted gene to the position previously occupied by gene E has been proposed. A potential
recombination leading to the rescue of gene E would lead to the loss of the essential gene
(Enjuanes, 2005).
An alternative approach for developing safer, recombination resistant live coronavirus vaccines
has been developed by modifying the transcriptional regulatory sequences (TRS) of a vaccine
strain to a sequence incompatible with the TRS of any known circulating coronavirus. The idea
being that recombinant events between wt coronaviruses and TRS remodeled SARS-CoV
would result in genomes containing lethal mixed regulatory sequences that block expression
of subgenomic mRNAs (Fig. 7A) (Yount et al., 2006). TRS sequences among coronaviruses
are highly conserved and direct the expression of subgenomic mRNAs. Using a molecular
clone, the SARS-CoV TRS network was remodeled from ACGAAC to CCGGAT (Fig. 7B).
This rewiring of the genomic transcription network allows for efficient replication of the mutant
virus, icSARS-CRG. The icSARS-CRG recombinant virus replicated to titers equivalent to
wt virus and expressed the typical ratios of subgenomic mRNAs and proteins. Interestingly,
some new transcripts were noted initiating from the replicase gene, most of which could encode
N-terminal truncated ORF1a polyproteins. It is not clear if these novel transcripts might
influence pathogenic outcomes, although in some instances nsp3 is truncated potentially
allowing for the establishment of dominant negative phenotypes on replication in cell culture
and animals. An attractive SARS-CoV vaccine could further be modified by building
attenuating mutations on the genetic template of the recombination-resistant TRS rewired virus
either for use as a safe, high titer seed stock for making killed vaccines or as a live virus vaccine.
One interesting refinement of this approach would be to include secondary traps that are
activated in recombinant genomes. In this instance, wt TRS sequences can be designed into
intragenic sites in essential ORFs like the S and M glycoprotein genes. In recombinant viruses
encoding wt leader TRS sequences, subgenomic transcription might initiate from within the
essential structural genes and the resulting N-terminal deletions would likely be lethal or
severely attenuating.
10. Potential side effects of SARS-CoV vaccines
Both humoral and T-cell-mediated responses to animal coronaviruses may exacerbate disease
or cause new health problems (Zhong et al., 2005). T-cell responses have been implicated in
the demyelinization of the brain and spinal cord following infection with neurotropic MHV
(Castro and Perlman, 1995; Wu et al., 2001), a group 2 coronavirus like SARS-CoV. Adverse
humoral responses to another group 2 coronavirus, bovine coronavirus (BCoV), have also been
linked to the development of “shipping fever” in cattle (O’Connor et al., 2001). Moreover,
previous exposure to FIPV, or passive or active immunization against this virus, a group 1
coronavirus, was found to cause the “early death syndrome” instead of providing immune
protection (Pedersen et al., 1981; Weiss et al., 1980). This disease exacerbation was due to the
virus-specific antibodies that facilitated and enhanced uptake and spread of the virus, causing
ADE of infectivity (Porterfield, 1986; Vennema et al., 1990; Weiss and Scott, 1981), that is
caused by spike protein specific antibodies (Corapi et al., 1995; Corapi et al., 1992; Olsen et
al., 1993; Olsen et al., 1992).
With this scenario of side effects caused by some coronavirus vaccines, a safety concern is that
SARS-CoV could induce similar antibody- or cell-mediated immune pathologies. This concern
was increased mainly by three reports. One study utilizing lentivirus pseudotyped with various
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SARS-CoV S proteins (Yang et al., 2005) indicated that within the S protein, the major target
for vaccine and immunotherapy, there are minor differences among eight strains transmitted
during human outbreaks in early 2003, whereas substantial functional changes were detected
in S derived from a case in late 2003 from Guandong province (isolate GD03) and from two
palm civets (SZ16 and SZ3). The GD03 spike pseudotyped virus is markedly resistant to
antibody neutralization. Alternatively, antibodies that neutralized most human S glycoproteins,
enhanced virus entry mediated by two civet cat virus S glycoproteins related to the GD03 isolate
(Yang et al., 2005). In another report, it has been shown that the administration into ferrets of
MVA-based SARS-CoV S vaccine, but not MVA alone, followed by live SARS-CoV
challenge, resulted in enhanced hepatitis (Weingartl et al., 2004). These side effects have not
been reported in other studies with SARS-CoV in ferrets, in which it has been shown that ferrets
are a useful model for SARS-CoV (Martina et al., 2003). Similarly, these data were not
reproduced by other groups (He et al., 2006). Furthermore, ADE of disease has not been
observed with any human SARS-CoV strain, therefore it will be important to assess vaccines
in relevant animal models as they become available. Antibodies directed against SARS-CoV
were found to be protective and not to enhance viral infectivity in the mouse or hamster models
(Bisht et al., 2004; Roberts et al., 2005b; Subbarao et al., 2004; Yang et al., 2004), using
inactivated SARS-CoV or immunization with recombinant adenovirus vectors expressing the
S and N proteins of SARS-CoV (See et al., 2006), although their effect in humans remains
unknown (Zhong et al., 2005). Side effects have not been observed in other animal models
such as African green monkeys that, 2 months after administration of SARS-CoV into the
respiratory tract, were challenged with SARS-CoV and no evidence of enhanced disease upon
re-challenge was shown (McAuliffe et al., 2004).
Consistent with these results, cynomolgus macaques immunized with different amounts of
purified virus, in the absence or the presence of adjuvant, challenged by the nasal route 30 days
post-immunization showed no side effects even in the presence of low titer neutralizing
antibodies. Temperature, breathing, appetite, mental state, and all biochemical indexes were
normal for immunized monkeys, and no abnormalities were observed in major organs such as
lung, liver, kidney, etc. All control non-vaccinated animals showed interstitial pneumonia.
These results indicate that the purified SARS-CoV vaccine is safe in monkeys (Qin et al.,
2006). In summary, immunization of mice using either S protein or whole inactivated virus
(Spruth et al., 2006), or of monkeys with whole inactivated SARS-CoV (Qin et al., 2006; Zhou
et al., 2005), most frequently resulted in the absence of side effects after providing different
types of SARS-CoV vaccines.
In contrast, VEE virus expressing N protein failed to induce protection in either young or
senescent animals, and resulted in enhanced immunopathology following viral challenge
between days 4 and 14 post-infection. Therefore, caution has to be taken before including N
in vaccine formulations by expressing N protein using DNA immunization, or VEE vectors
(Deming et al., 2006), as no protection was elicited in mice against homologous challenge, and
no benefit to vaccination with a cocktail of both S and N proteins was observed. Rather, the
co-expression of N protein in vaccine regimens which failed to simultaneously induce a strong
neutralizing anti-S antibody response led to an increased number of lymphocytic and
eosinophilic inflammatory infiltrates, which are also characteristic of the immune pathology
observed with respiratory syncytial virus (RSV) infection following vaccination with formalin
inactivated RSV (De Swart et al., 2002; Hancock et al., 1996). Therefore, the concern has been
raised that expression of N protein may result in vaccine-enhanced pulmonary disease, as
previously described for viruses like RSV (Kim et al., 1969). The data suggest that the presence
of N protein in vaccines should be evaluated in each vaccine formulation (Deming et al.,
2006). Although thus far, no human SARS-CoV S vaccine has been shown to be involved in
ADE of disease, possible immunopathological complications of SARS vaccine candidates
require rigorous clinical and immunological evaluation.
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11. Concluding remarks
Whereas the production of effective and safe vaccines for animal coronavirus previously
reported has not been satisfactory (Cavanagh, 2003; Enjuanes et al., 1995; Saif, 2004), the
production of inactivated, subunit, or vaccines based on DNA, recombinant vectors, or by
reverse genetics using SARS-CoV genomes seem more promising. An optimum animal model
for SARS-CoV vaccine evaluation is still required. After preclinical trials in animal models
efficacy and safety evaluation of the most promising vaccine candidates described has to be
performed in humans.
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Fig. 1.
Phylogenetic analysis of human, bat, and civet cat-racoon dog virus spike sequences. An
unrooted Bayesian phylogenetic gene tree of 24 SARS viruses divided into four groups. Group
1 includes viruses isolated from animals in southern China in 2003. Group 2 is a cluster of
viruses isolated from animals and humans (*) in 2003. Group 3 includes viruses from all three
phases of the human SARS epidemic of 2002–2003. Group 4 represents a cluster of viruses
isolated from bats in 2005–06. A multiple sequence alignment of the spike gene of each virus
was created using ClustalX 1.83 with default settings. Bayesian inference was conducted with
Mr. Bayes, with Markov chain Monte Carlo sampling of four chains for 500,000 generations,
and a consensus tree was generated using the 50% majority rule with a burn in of 1000. Branch
confidence values are shown as posterior probabilities. The three human isolates that fall within
the animal cluster (GZ0402, GD03, and GZ0401) may represent infections where a human
acquired the virus from animals. The dashed line between Group 3 and Group 4 is used to
represent a much longer line in the tree (~10 times longer), thus the distance of the line is not
representative of the distance between bat and human SARS.
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Fig. 2.
Structure and genome organization of SARS-CoV. (A). Schematic diagram of SARS-CoV
structure. S, spike protein; M, membrane protein; E, envelope protein; N, nucleoprotein; 3a,
7a, and 7b, structural proteins of SARS-CoV. (B). Representation of a prototype SARS-CoV
genome. Poly(A) tail is indicated by AAA. Numbers and letters indicate viral genes.
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Fig. 3.
Neutralization of SARS-CoV pseudotypes and heterologous challenge studies. (A) Cross
neutralization responses between wt Urbani (^) and icGD03 (▪). About 100 PFU of each virus
was incubated for 30 min with varying concentrations of human antisera from a convalescent
SARS patient or control serum and titered by plaque assay. (B) Compilation of vaccination
results in mice inoculated with VRP-vectored vaccines and challenged with icSARS or
icGDO3-S (Deming et al., 2006). The percent of mice without detectable replicating virus are
shown as bars while the average titers of detectable virus are shown as red circles. Error bars
represent the standard deviation of the measured samples. Mice were vaccinated with VRP-S,
VRP-N, a cocktail of VRP-S and VRP-N (VRP-S+N), or mock vaccinated with either VRP-
HA (VRP expressing influenza A HA protein) or PBS. Mice were intranasally challenged with
either Urbani derived from the infectious clone (icSARS) or a chimeric virus expressing the
GD03 spike glycoprotein (GD03-S). Mice challenged with icSARS were vaccinated when
young (4–5 weeks), boosted 4 weeks later, and challenged either 8 weeks post boost (young)
or 54 weeks post boost when old (Senescent). VRP-S and VRP-S+N provided protection in
both groups against icSARS. Mice challenged with GD03-S were either vaccinated when 7
weeks old (young) or older than 26 weeks old (senescent), boosted approximately 4 weeks
later, and challenged either 7 weeks post boost (young) or 32 weeks post boost (senescent).
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Fig. 4.
Propagation of SARS-CoV with a deleted E gene in different cell lines. Vero E6 (A), Huh-7
(B), and CaCo-2 (C) cells were infected at a moi of 0.5 with either the rSARS-CoV-ΔE or the
recombinant wild-type virus. At different times post-infection, virus titers were determined by
plaque assay on Vero E6 cells. Error bars represent standard deviations from the mean from
three experiments.
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Fig. 5.
Assembly of SARS-CoV-ΔE deletion mutant in the ERGIG compartment. Electron
micrographs of Vero E6 cells infected (moi 1.0) with SARS-CoV (A) and SARS-CoV-ΔE (B)
at 24 h post-infection.
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Fig. 6.
Growth of rSARS-CoV in the respiratory tract of hamsters. Hamsters were inoculated with
103TCID50 of rSARS-CoV or rSARS-CoV-ΔE. Animals were sacrified and tissues were
harvested at different times post-infection. Viral titers in lung (A) and nasal turbinates (B) were
determined in Vero E6 cells monolayers. The non-parametric Mann–Whitney U-statistical
method was used for ascertaining the significance of observed differences. Statistical
significance was indicated by (*p-value < 0.05). The dotted line indicates the lower limit of
detection.
Enjuanes et al. Page 31
Virus Res. Author manuscript; available in PMC 2009 January 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 7.
(A) Genome organization of SARS-CoV recombinant viruses to generate safe attenuated
viruses. The wild-type SARS-CoV TRS, ACGAAC (blue circles), were changed to CCGGAT
(red circles). Since the wild-type and mutant TRS signals are not compatible in regulating
subgenomic transcription (Yount et al., 2006), a recombination event resulting in a viral
genome with mixed TRS signals is not viable. (B) The icSARS-CoV TRS sequence is unique
from that of other described coronaviruses. TRS sequences for select group 1, 2 and 3
coronaviruses are summarized. The TRS selected for the remodeled virus is shown at the
bottom.
Enjuanes et al. Page 32
Virus Res. Author manuscript; available in PMC 2009 January 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
